flavin-mononucleotide and Pyelonephritis

The results of investigation of the clinical efficiency of using the antioxidant drug cytoflavin in a complex therapy of patients with chronic pyelonephritis prior to development of azotemia are presented. It is shown that cytoflavin in combination with basic therapy reduces the intensity of lipid peroxidation processes (as monitored using diene conjugates, malonic dialdehyde, and Schiffbase metabolites) with retention of the antioxidant status. The proposed treatment normalizes the ratio of blood plasma phospholipid fractions and erythrocytes membranes.

Topics: Adult; Antioxidants; Azotemia; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Erythrocyte Membrane; Erythrocytes; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Lipid Peroxidation; Lipid Peroxides; Male; Middle Aged; Niacinamide; Phospholipids; Pyelonephritis; Succinates